This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiederhold, N. P.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiederhold, N. P.
Right arrow Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1616-1620, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.00105-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera{triangledown}

Nathan P. Wiederhold,1,2* Laura K. Najvar,2 Rosie Bocanegra,2 Destiny Molina,2 Marcos Olivo,2 and John R. Graybill2

College of Pharmacy, The University of Texas at Austin, Austin, Texas,1 Department of Medicine/Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, Texas2

Received 24 January 2007/ Returned for modification 30 January 2007/ Accepted 12 February 2007

In vitro studies have demonstrated that anidulafungin has greater potency than caspofungin against Candida glabrata. However, data from in vivo studies demonstrating that it has superior efficacy are lacking. The objective of this study was to compare the activities of anidulafungin and caspofungin against C. glabrata in a murine model of disseminated candidiasis. Two clinical C. glabrata isolates were used, including one with reduced caspofungin susceptibility. MICs were determined by broth microdilution in the presence and absence of sera. For the animal studies, mice were immunosuppressed with 5-fluorouracil one day prior to intravenous inoculation. Treatment with anidulafungin and caspofungin (0, 0.5, 1, 5, and 10 mg/kg of body weight per day) was begun 24 h later and was continued through day 7 postinoculation. The CFU were enumerated from kidney tissue. According to the standard microdilution methodology, anidulafungin had superior in vitro activity. However, this enhanced potency was attenuated by the addition of mouse and human sera. Caspofungin reduced the kidney fungal burden at lower doses compared to that achieved with anidulafungin in mice infected with the isolate with the lower MIC. Against the strain with the elevated caspofungin MIC, both anidulafungin and caspofungin were effective in reducing the kidney fungal burden at the higher doses studied. Despite the greater in vitro activity of anidulafungin in the absence of sera, both echinocandins were similarly effective in reducing the fungal burden in kidney tissue. The superior in vitro activity of anidulafungin did not confer enhanced in vivo efficacy against C. glabrata.


* Corresponding author. Mailing address: UTHSCSA, PERC, MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-8340. Fax: (210) 567-8328. E-mail: wiederholdn{at}uthscsa.edu

{triangledown} Published ahead of print on 16 February 2007.


Antimicrobial Agents and Chemotherapy, May 2007, p. 1616-1620, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.00105-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Ostrosky-Zeichner, L., Paetznick, V. L., Rodriguez, J., Chen, E., Sheehan, D. J. (2009). Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-{beta}-D-Glucan Levels. Antimicrob. Agents Chemother. 53: 1639-1641 [Abstract] [Full Text]  
  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Maida, C. M., Milici, M. E., Trovato, L., Oliveri, S., Amodio, E., Spreghini, E., Scalise, G., Barchiesi, F. (2008). Evaluation of the Disk Diffusion Method Compared to the Microdilution Method in Susceptibility Testing of Anidulafungin against Filamentous Fungi. J. Clin. Microbiol. 46: 4071-4074 [Abstract] [Full Text]  
  • Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., Lee, S. A. (2008). Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52: 4145-4148 [Abstract] [Full Text]  
  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  
  • Thompson, G. R. III, Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S. II, Patterson, T. F. (2008). Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrob. Agents Chemother. 52: 3783-3785 [Abstract] [Full Text]  
  • Cota, J. M., Grabinski, J. L., Talbert, R. L., Burgess, D. S., Rogers, P. D., Edlind, T. D., Wiederhold, N. P. (2008). Increases in SLT2 Expression and Chitin Content Are Associated with Incomplete Killing of Candida glabrata by Caspofungin. Antimicrob. Agents Chemother. 52: 1144-1146 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]